SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

13 May 2022 Evaluate
A minor change in the total revenue was seen in the March 2022 quarter. The total revenue for the quarter stood at Rs. 20063.10 millions against Rs. 19174.70 millions during year ago period.A big loss of -78.81% reported for the quarter ended March 2022 to Rs. 768.80  millions from Rs. 3627.40 millions.Operating Profit reported a sharp decline to 2539.20 millions from 4651.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 20063.10 19174.70 4.63 88298.10 72196.80 22.30 88298.10 72196.80 22.30
Other Income 542.30 487.70 11.20 1998.90 1900.10 5.20 1998.90 1900.10 5.20
PBIDT 2539.20 4651.80 -45.41 20102.50 21389.40 -6.02 20102.50 21389.40 -6.02
Interest 130.80 73.60 77.72 379.00 429.30 -11.72 379.00 429.30 -11.72
PBDT 2408.40 4450.40 -45.88 19723.50 20832.30 -5.32 19723.50 20832.30 -5.32
Depreciation 550.10 493.80 11.40 2189.80 1989.30 10.08 2189.80 1989.30 10.08
PBT 1858.30 3956.60 -53.03 17533.70 18843.00 -6.95 17533.70 18843.00 -6.95
TAX 1089.50 329.20 230.95 2121.20 1992.20 6.48 2121.20 1992.20 6.48
Deferred Tax 765.40 -380.20 -301.32 -917.00 -1326.10 -30.85 -917.00 -1326.10 -30.85
PAT 768.80 3627.40 -78.81 15412.50 16850.80 -8.54 15412.50 16850.80 -8.54
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 12.66 24.26 -47.83 22.77 29.63 -23.15 22.77 29.63 -23.15

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×